Halozyme Therapeutics (HALO) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Halozyme Therapeutics (HALO) PT Cut to $15 at Piper Jaffray
November 11, 2014 7:35 AM ESTPiper Jaffray analyst Charles Duncan lowered his price target on Halozyme Therapeutics (NASDAQ: HALO) to $15.00 (from $20.00) following Q3 results but retained an Overweight rating.
Duncan commented, "Halozyme reported 3Q earnings yesterday, ending the quarter with $135M, which we view as still potentially... More
